Intensity TherapeuticsINTS
13F holders, Q3 2024 (September 30)20holders −3
1new positions
4sold out
$3.82avg. 13F price*
At the end of Q3 2024, 20 institutions reported holding Intensity Therapeutics Inc. (INTS) in their 13F filings, down 3 from Q2 2024. 1 opened new positions and 4 sold out. The largest holders were Sapient Capital LLC ($3.9M), Vanguard Group Inc. ($798K) and Brown Advisory Inc. ($566K).
- Company
- Intensity Therapeutics Inc.
- CUSIP
- 45828J103
- Latest filing quarter
- Q4 2025
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $142K |
| Exits | 4 | $81K |
All 13F filers, Q2 2024 → Q3 2024: 80,800 shares bought and 27,745 shares sold, net +53,055 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 20 holders
| Sapient Capital LLC | 0.08% | No change | 1,010,753 | $3.9M |
| Vanguard Group Inc. | 0.00% | Add +1.9% | 208,886 | $798K |
| Brown Advisory Inc. | 0.00% | Reduce -6.0% | 148,109 | $566K |
| Geode Capital Management, LLC | 0.00% | Add +35.1% | 64,349 | $246K |
| Sigma Planning Corp | 0.01% | Reduce -0.3% | 47,744 | $182K |
| Mesirow Financial Investment Management, Inc. | 0.00% | No change | 44,177 | $169K |
| Blair William & Co. | 0.00% | No change | 37,805 | $144K |
| GTS Securities LLC | 0.00% | New | 37,288 | $142K |
| One Charles Private Wealth Services, LLC | 0.05% | No change | 31,800 | $121K |
| BlackRock, Inc. | 0.00% | — | 22,113 | $84K |
| UBS Group AG | 0.00% | Add +521.5% | 20,609 | $79K |
| Rothschild Wealth LLC | 0.02% | Add +41.8% | 18,918 | $72K |
| Bison Wealth, LLC | 0.01% | No change | 17,420 | $67K |
| State Street Corp. | 0.00% | No change | 14,500 | $55K |
| Commonwealth Equity Services, LLC | 0.00% | No change | 10,414 | $40K |
| Wells Fargo & Company | 0.00% | No change | 3,450 | $13K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -50.3% | 1,169 | $4K |
| Morgan Stanley | 0.00% | No change | 500 | $2K |
| Bank of America Corp. | 0.00% | Reduce -77.6% | 49 | $187 |
| JPMorgan Chase & Co. | 0.00% | Reduce -5.6% | 17 | $65 |
"% of holder's portfolio" is INTS's weight in each manager's 13F, not the share of Intensity Therapeutics Inc. the manager owns.